EZH2 and acute myeloid leukemia: We found that the EZH2 inhibitor UNC1999 greatly increased the effect of PARP inhibitor olaparib against BRCA-deficient Lin-CD34+ AML cells, whereas normal bone marrow counterparts were only modestly sensitive (Figure 9B).